[1]李苗苗,王玉红,刘 静.中国沈阳地区汉族冠心病患者CYP2C19基因多态性分布特征[J].现代检验医学杂志,2019,34(02):5-8.[doi:10.3969/j.issn.1671-7414.2019.02.002]
　LI Miao-miao,WANG Yu-hong,LIU jing.Distribution Characteristics of CYP2C19 Gene Polymorphismin Han Patients with Coronary Heart Disease in Shenyang,China[J].Journal of Modern Laboratory Medicine,2019,34(02):5-8.[doi:10.3969/j.issn.1671-7414.2019.02.002]
点击复制

中国沈阳地区汉族冠心病患者CYP2C19基因多态性分布特征()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年02期
页码:
5-8
栏目:
论著
出版日期:
2019-05-11

文章信息/Info

Title:
Distribution Characteristics of CYP2C19 Gene Polymorphismin Han Patients with Coronary Heart Disease in Shenyang,China
文章编号:
1671-7414(2019)02-005-05
作者:
李苗苗1; 2; 王玉红1; 刘 静1
(1.北部战区总医院检验科,沈阳 110016; 2.大连医科大学研究生院,辽宁大连 116044)
Author(s):
LI Miao-miao1; 2; WANG Yu-hong1; LIU jing1
(1.Department ofClinical Laboratory,Northern Theater Command General Hospital,Shenyang 110016,China; 2.Postgraduate College,Dalian Medical University,Liaoning Dalian116044,China)
关键词:
冠心病;  CYP2C19;  基因多态性;  氯吡格雷代谢型
分类号:
R541.4; Q786
DOI:
10.3969/j.issn.1671-7414.2019.02.002
文献标志码:
A
摘要:
目的 探讨沈阳地区汉族冠心病(coronary heart disease,CHD)患者细胞色素P450 2C19(CYP2C19)基因多态性分布特征。方法 选取2016年1月～2018年1月于北部战区总医院(原沈阳军区总医院)入院接受治疗的冠心病患者2 748例,应用聚合酶链反应微阵列芯片杂交方法检测患者氯吡格雷代谢相关的CYP2C19基因型。根据性别、年龄因素对患者进行分组。采用四格表资料的χ2检验,R×C表资料的χ2检验比较各组间冠心病患者氯吡格雷代谢相关的CYP2C19*1,*2,*3基因型,*2,*3等位基因频率,及氯吡格雷代谢型的分布差异。结果 沈阳地区汉族冠心病患者CYP2C19*1/*1,CYP2C19*1/*2,CYP2C19*1/*3,CYP2C19*2/*2,CYP2C19*3/*3和CYP2C19*2/*3发生率分别为41.7%,39.3%,5.8%,9.8%,0.4%和3.0%; CYP2C19*2,CYP2C19*3等位基因频率分别为31.0%和4.8%; 氯吡格雷快代谢型(EM),氯吡格雷中间代谢型(IM),氯吡格雷慢代谢型(PM)发生率分别为41.7%,45.1%和13.2%。根据性别分组,患者CYP2C19*2,*3等位基因,氯吡格雷代谢型,CYP2C19的6种基因型在不同性别冠心病患者中的分布差异均无统计学意义(χ2=0.032～9.205,均P>0.05)。根据年龄分组<45岁,45～59岁,60～75岁,>75岁,患者CYP2C19*2,*3等位基因,CYP2C19的6种基因型在不同年龄冠心病患者中的分布差异均有统计学意义(χ2=17.718～48.772,均P≤0.001),氯吡格雷代谢型在不同年龄冠心病患者中的分布差异无统计学意义(χ2=4.442,P=0.617)。结论 沈阳地区汉族冠心病患者CYP2C19的6种基因型,CYP2C19*2,*3等位基因分布与沈阳地区汉族冠心病患者性别差异无关,与年龄分层密切相关。
Abstract:
Objective To investigate the distribution of Cytochrome P450 2C19(CYP2C19)gene polymorphism in Han patients with coronary heart disease(CHD)in Shenyang.Methods The genotype of CYP2C19 related to clopidogrel metabolic was detected by polymerase chain reactionmicroarray hybridization in 2 748 Han patients with coronary heart disease admitted to the Northern Theater Command General Hospital from January 2016 to January2018.The patients were grouped according to gender and age.Chi-square test was adopted to analysis the six differences of CYP2C19 genotypes,allele distribution of *2 and *3 in different age and sex CHD patients.Results The frequencies of CYP2C19*1/*1,CYP2C19*1/*2,CYP2C19*1/*3,CYP2C19*2/*2,CYP2C19*3/*3 and CYP2C19*2/*3 in Han patients with coronary heart disease in Shenyang,China were 41.7%,39.3%,5.8%,9.8%,0.4% and 3.0% respectively,the frequencies of CYP2C19*2 and CYP2C19*3 alleles were 31.0% and 4.8% respectively, extensive metabolizers(EM),intermediate metabolizers(IM)and poor metabolizers(PM)were 41.7%,45.1% and 13.2% respectively in Han patients withCHD in Shenyang.There was no statistically significant in the distribution ofCYP2C19*2 and *3 alleles,clopidogrel metabolic type and CYP2C19 genotypes amongpatients of different gender with coronary heart disease(χ2=0.032～9.205,all P>0.05).There was statistically significant in the distribution ofCYP2C19*2,*3 allele and CYP2C19 genotypes in patients of different ages with coronary heart disease was significantly different according to age groups <45y,45～59y,60～75y and >75y(χ2=17.718～48.772,all P≤0.001).There was no statistically significant in the distribution of patients and clopidogrel metabolic type in patients with coronary heart disease at different ages(χ2=4.442,P=0.617).Conclusion The distribution of CYP2C19 * 2,* 3 alleles and 6 genotypes of CYP2C19 in CHD patients of Han nationality in Shenyang areawas related with age,and not related with gender.

参考文献/References:

[1] 中国医师协会急诊医师分会,中华医学会心血管病学会,中华医学会检验医学分会.急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397-404. Emergency Medical Branch of Chinese Medical Doctor Association,Cardi Vascular Epidemiology Branch of Chinese Medical Association,Laboratory Medicine Branch of Chinese Medical Association.Emergency rapid diagnosis and treatment of guidelines acute coronary syndrome[J].Chinese Journal of Emergency Medicine,2016,25(4):397-404.
[2] LEVINE G N,BATES E R,BITTL J A,et al.Correction to:Duration of dual antiplatelet therapy:A systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary arterydisease:A report of the American college of cardiology/American heart association task force on clinical practice guidelines[J].Circulation,2016,134(10):e195-197.
[3] BOZZI L M,MITCHELL B D,LEWIS J P,et al.The pharmacogenomics of anti-platelet intervention(PAPI)study:variation in platelet response to clopidogrel and aspirin[J].Current Vascular Pharmacology,2016,14(1):116-124.
[4] LEE J H,BASITH S,CUI M,et al.In silico prediction of multiple-category classification model for cytochrome P450 inhibitors and non-inhibitors usingmachine-learning method[J].SAR and QSAR in Environmental Research,2017,28(10):863-874.
[5] LIU Rui,ZHOU Ziyi,CHEN Yibei,et al.Associations of CYP3A4,NR1I2,CYP2C19and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke[J].Acta Pharmacologica Sinica,2016,37(7):882-888.
[6] 吴薇,王丽岳,李艳.DNA微阵列芯片法与直接测序法检测CYP2C19基因型的比较研究[J].现代检验医学杂志,2016,31(2):8-11. WU Wei,WANG Liyue,LI Yan.Comparison analysis of CYP2C19 polymorphism detection by DNA microarray and DNA microarray[J].Journal of Modern Laboratory Medicine,2016,31(2):8-11.
[7] CAVALLARI L H,FRANCHI F,ROLLINI F, et al.Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention[J].Journal of Translational Medicine,2018,16(1):92.
[8] DEHBOZORGI M,KAMALIDEHGHAN B,HOSS-EINI I,et al.Prevalence of the CYP2C19*2(681 G>A), *3(636 G>A)and *17(806 C>T)alleles among an Iranian population of different ethnicities[J].Molecular Medicine Reports,2018,17(3):4195-4202.
[9] STASIUKONYTE N, LIUTKEVICIENE R, VILK-EVICIUTE A, et al. Associationsbetween Rs4244285 and Rs762551 gene polymorphisms and age-related macular degeneration[J].Ophthalmic Genetics,2017,38(4):357-364.
[10] DU Xue, PI Yipi, DREYER RP, et al.The china patient-centered evaluative assessment of cardiac events(PEACE)prospective study of percutaneous coronary intervention:Study design[J].Catheterization and Cardiovascular Interventions,2016,88(7):E212-e221.
[11] WEI Youquan,WANG Diangang,YANG Hao,et al.Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome[J].PLoS One,2015,10(7):e0132561.
[12] MARTINEZ-QUINTANA E,RODRIGUEZ-GONZ-ALEZ F,MEDINA-GIL JM,et al.CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome[J].Medicina Clinica,2017,149(6):235-239.
[13] HOKIMOTO S,TABATA N,AKASAKA T,et al.Gender differences in impact ofCYP2C19 polymorphism on development of coronary artery disease[J].J Cardiovasc Pharmacol,2015,65(2):148-152.
[14] AKASAKA T,SUETA D,ARIMA Y,et al.Association of CYP2C19 variants andepoxyeicosatrienoic acids on patients with microvascular angina[J].American Journal of Physiology Heart and Circulatory Physiology,2016,311(6):H1409-H1415.
[15] 曾敏,熊怡淞,俞娟,等.四川地区冠心病患者CYP2C19基因多态性检测 [J].检验医学与临床,2017,14(10):1363-1365.ZENG Min, XIONG Yisong,YU Juan,et al.Genetic polymorphism analysis ofCYP2C19 in patients with coronary heart disease in Sichuan Province[J].Laboratory Medicine and Clinic,2017,14(10):1363-1365.
[16] 华仙丽,梁爱芬,雷亚利,等.广东东莞地区心血管疾病患者CYP2C19基因多态性分析[J].国际检验医学杂志,2017,38(5):606-608.HUA Xianli,LIANG Aifen,LEI Yali,et al.Analysis on CYP2C19 polymorphism among patients with cardiovascular disease in Dongguan area[J].International Journal of Laboratory Medicine,2017,38(5):606-608.
[17] 韩瑞玲,李艳,吴薇.武汉地区冠心病患者氯吡格雷药物代谢相关基因CYP2C19的多态性分布分析[J].现代检验医学杂志,2015,30(3):21-23.HAN Ruiling,LI Yan,WU Wei,Analysis of dolymorphism distribution of clopidogrel metabolism related gene CYP2C19 in patients with coronary artery diseasein wuhan[J].Journal of Modern Laboratory Medicine,2015,30(3):21-23.
[18] FORD NF,TAUBERT D.Clopidogrel,CYP2C19,and a Black Box[J].Journal of Clinical Pharmacology,2013,53(3):241-248.

相似文献/References:

[1]吴 薇,王丽岳,李 艳.DNA微阵列芯片法与直接测序法检测CYP2C19基因型的比较研究[J].现代检验医学杂志,2016,31(02):8.[doi:10.3969/j.issn.1671-7414.2016.02.003]
　WU Wei,WANG Li-yue,LI Yan.Comparison Analysis of CYP2C19 Polymorphisms Detection by DNA Microarray and DNA Microarray[J].Journal of Modern Laboratory Medicine,2016,31(02):8.[doi:10.3969/j.issn.1671-7414.2016.02.003]
[2]韩瑞玲,李 艳,吴 薇.武汉地区冠心病患者氯吡格雷药物代谢相关基因CYP2C19的多态性分布分析[J].现代检验医学杂志,2015,30(03):21.[doi:10.3969/j.issn.1671-7414.2015.03.006]
　HAN Rui-ling,LI Yan,WU Wei.Analysis of the Polymorphism Distribution of Clopidogrel Metabolism Related Gene CYP2C19 in Patients with Coronary Artery Disease in Wuhan[J].Journal of Modern Laboratory Medicine,2015,30(02):21.[doi:10.3969/j.issn.1671-7414.2015.03.006]
[3]洪骏,王锋,印中鹏,等.冠心病患者血浆纤维蛋白原与脂蛋白相关磷脂酶A2水平[J].现代检验医学杂志,2015,30(05):6.[doi:10.3969/j.issn.1671-7414.2015.05.003]
　HONG Jun,WANG Feng,YIN Zhong-peng,et al.Levels of Plasma Lipoprotein Associated Phospholipase A2 and Fibrinogen in Patients with Coronary Artery Disease[J].Journal of Modern Laboratory Medicine,2015,30(02):6.[doi:10.3969/j.issn.1671-7414.2015.05.003]
[4]赵佳a,姚创利a,左林,等.冠心病患者血清同型半胱氨酸对血脂和锰超氧化物歧化酶的影响[J].现代检验医学杂志,2015,30(05):44.[doi:10.3969/j.issn.1671-7414.2015.05.013]
　ZHAO Jiaa,YAO Chuang-lia,ZUO Lin,et al.Effects of Homocysteine on Blood Lipid and Manganese Superoxide Dismutase in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(02):44.[doi:10.3969/j.issn.1671-7414.2015.05.013]
[5]李 垚,杨 平.早发冠心病触珠蛋白水平及其在免疫调节中的作用研究[J].现代检验医学杂志,2015,30(01):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
　LI Yao,YANG Ping.Role of Haptoglobin in the Immunomodulatory in Patients with Premature Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(02):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
[6]张 蕾,陈 捷,陈玉婷.冠心病并发恶性肿瘤患者Ghrelin/obestatin比值变化及意义[J].现代检验医学杂志,2016,31(04):104.[doi:10.3969/j.issn.16717-414.2016.04.029]
　ZHANG Lei,CHEN Jie,CHEN Yu-ting.Change and Significance of Ghrelin/Obestatin in Patients with Coronary Heart Disease Complicated with Malignant Tumor[J].Journal of Modern Laboratory Medicine,2016,31(02):104.[doi:10.3969/j.issn.16717-414.2016.04.029]
[7]赵 佳,左 林,姚创利,等.冠心病患者血清同型半胱氨酸水平与氧化应激的关系研究[J].现代检验医学杂志,2016,31(05):27.[doi:10.3969/j.issn.1671-7414.2016.05.007]
　ZHAO Jia,ZUO Lin,YAO Chuang-li,et al.Study on the Relationship between Serum Homocysteine Levels and Oxidative Stress in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2016,31(02):27.[doi:10.3969/j.issn.1671-7414.2016.05.007]
[8]姚创利,黎 阳,鲁旭娟,等.超氧化物歧化酶及其同工酶和超敏C-反应蛋白与冠心病的关系[J].现代检验医学杂志,2016,31(05):73.[doi:10.3969/j.issn.1671-7414.2016.05.019]
　YAO Chuang-li,LI Yang,LU Xu-juan,et al.Relationship of Superoxide Dismutase Isoenzyme and High Sensitive C-Reactive Protein with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2016,31(02):73.[doi:10.3969/j.issn.1671-7414.2016.05.019]
[9]黄生金,郑利平,陆俊佳,等.广西地区壮族和汉族冠心病患者胱抑素C水平及其基因多态性的比较研究[J].现代检验医学杂志,2017,32(03):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
　HUANG Sheng-jin,ZHENG Li-ping,LU Jun-jia,et al.Comparative Study of Cystatin C and Its Gene Polymorphism of Pati ents with Coronary Heart Disease between Zhuang and Han in Guangxi Region[J].Journal of Modern Laboratory Medicine,2017,32(02):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
[10]葛高顺,倪二茹,方宜臻,等.厦门地区心血管疾病患者外周血单个核细胞CYP2C19基因型与表型的分布研究[J].现代检验医学杂志,2018,33(04):8.[doi:10.3969/j.issn.1671-7414.2018.04.003]
　GE Gao-shun,NI Er-ru,FANG Yi-zhen,et al.Study on the Distribution of CYP2C19 Genotypes and Phenotypes Mononuclear Cells of Peripheral Blood from Patients with Cardiovascular Diseases in Xiamen Area[J].Journal of Modern Laboratory Medicine,2018,33(02):8.[doi:10.3969/j.issn.1671-7414.2018.04.003]

备注/Memo

备注/Memo:
作者简介:李苗苗(1993-),女,在读硕士研究生,主要从事临床检验诊断方面研究,E-mail:819630044@qq.com。 通讯作者:刘 静(1986-),女,硕士,主管技师,主要研究方向:临床检验诊断,E-mail:jinjing8304@163.com。 收稿日期:2019-01-06 修回日期:2019-01-24 页码：8+13
更新日期/Last Update: 2019-04-30